

"Express Mail" Mailing Label No. EL901838665US
Date of Deposit December 11, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above, with sufficient postage affixed, and is addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.

Carol Williams

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)



Amelia
12/19/02

Patent
Attorney's Docket No. 033352-007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)

Eva A. Turley et al.)

Group Art Unit: 1653

Application No.: 09/685,010)

Examiner: S.W. Liu

Filed: October 5, 2000)

Confirmation No.: 5697

For: COMPOSITIONS AND METHODS FOR)
TREATING CELLULAR RESPONSE)
TO INJURY AND OTHER)
PROLIFERATING CELL DISORDERS)
REGULATED BY HYALADHERIN)
AND HYALURONANS)

AMENDMENT AND REPLY TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Amendment and Reply to Restriction Requirement is submitted in response to the Office Action requiring restriction of the claims mailed September 11, 2002. It is being submitted on or before the current due date of December 11, 2002 and a petition for a two month extension of time accompanies this response.

RECEIVED
DEC 17 2002
TECH CENTER 1600/2900

In the event that a telephone conversation could expedite the prosecution of this application, the Examiner is requested to telephone the undersigned at 650-622-2300 (extension 2330).

AMENDMENT

Please cancel Claim 37, without prejudice or disclaimer, amend Claims 1-4, 7, 8, 10 and 21, and add new Claim 38, so that the claims of this application read as follows:

01
--1. (amended) A method for treating a patient with an inflammatory or neurological disorder, comprising administering to a patient a compound selected from the group consisting of (a) a polypeptide comprising the amino acid sequence BX7B which binds HA; (b) an antibody which binds one of domains D1, D2, D3, D4, or, D5 of RHAMM; (c) a polypeptide fragment which comprises at least one D1, D2, D3, D4, or, D5 domain of RHAMM; and (d) a gene delivery vector which expresses antisense RHAMM, or, delivers and expresses any one of (a), (b), or (c), such that said inflammatory or neurological disorder is treated.

2. (amended) The method according to claim 1 wherein said disorder is Parkinsons disease.

3. (amended) The method according to claim 1 wherein said disorder is Alzheimer disease